一项研究单独或联合使用 LY3841136 和替西帕肽 (LY3298176) 对患有 2 型糖尿病的肥胖或超重成年参与者进行体重管理的研究
一项 2 期、平行组、双盲、安慰剂对照研究,旨在调查 LY3841136 和替西帕肽单独或联合用药对患有 2 型糖尿病的肥胖或超重成年参与者的体重管理
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Chandler、Arizona、美国、85225
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
-
Phoenix、Arizona、美国、85032
- HOPE Research Institute
-
Scottsdale、Arizona、美国、85260
- Headlands Research - Scottsdale
-
Tucson、Arizona、美国、85712
- The Institute for Liver Health II dba Arizona Liver Health-Tucson
-
-
California
-
Greenbrae、California、美国、94904
- NorCal Medical Research, Inc
-
Huntington Park、California、美国、90255
- Velocity Clinical Research, Huntington Park
-
Rolling Hills Estates、California、美国、90274
- Peninsula Research Associates
-
Walnut Creek、California、美国、94598
- Diablo Clinical Research, Inc.
-
-
Connecticut
-
Stamford、Connecticut、美国、06905
- Stamford Therapeutics Consortium
-
-
Florida
-
Fleming Island、Florida、美国、32003
- Northeast Research Institute (NERI)
-
Hialeah、Florida、美国、33012
- Indago Research & Health Center, Inc
-
Miami、Florida、美国、33165
- New Horizon Research Center
-
New Port Richey、Florida、美国、34652
- Suncoast Clinical Research, Inc.
-
Orlando、Florida、美国、32803
- Charter Research - Winter Park
-
The Villages、Florida、美国、32162
- Charter Research - Lady Lake
-
-
Idaho
-
Ammon、Idaho、美国、83406
- Medical Research Partners
-
-
Illinois
-
Chicago、Illinois、美国、60640
- Great Lakes Clinical Trials - Andersonville
-
Chicago、Illinois、美国、60640
- Great Lakes Clinical Trials - Ravenswood
-
Skokie、Illinois、美国、60077
- NorthShore University Health System
-
-
Iowa
-
West Des Moines、Iowa、美国、50266
- Iowa Diabetes and Endocrinology Research Center
-
-
Kansas
-
Topeka、Kansas、美国、66606
- Cotton O'Neil Diabetes & Endocrinology
-
-
Massachusetts
-
Needham、Massachusetts、美国、02492
- Knownwell
-
New Bedford、Massachusetts、美国、02740
- Lucida Clinical Trials
-
-
Michigan
-
Southfield、Michigan、美国、48034
- Headlands Research - Detroit
-
Troy、Michigan、美国、48098
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
-
-
Missouri
-
City of Saint Peters、Missouri、美国、63303
- StudyMetrix Research
-
Springfield、Missouri、美国、65807
- Clinvest Headlands Llc
-
-
Nevada
-
Las Vegas、Nevada、美国、89128
- Las Vegas Medical Research
-
-
New York
-
Amherst、New York、美国、14226
- Dent Neurologic Institute
-
East Syracuse、New York、美国、13057
- Velocity Clinical Research, Syracuse
-
Port Jefferson Station、New York、美国、11776
- North Suffolk Neurology
-
Rochester、New York、美国、14609
- Rochester Clinical Research, LLC
-
-
North Carolina
-
Greensboro、North Carolina、美国、27405
- Medication Management
-
Monroe、North Carolina、美国、28112
- Monroe Biomedical Research
-
Morehead City、North Carolina、美国、28557
- Lucas Research, Inc
-
New Bern、North Carolina、美国、28562
- Lucas Research, Inc.
-
-
Ohio
-
Cincinnati、Ohio、美国、45212
- CTI Clinical Research Center
-
-
South Carolina
-
Greenville、South Carolina、美国、29607
- Tribe Clinical Research, LLC
-
-
Tennessee
-
Nashville、Tennessee、美国、37211
- Quality Medical Research
-
-
Texas
-
Austin、Texas、美国、78745
- IMA Clinical Research Austin
-
Dallas、Texas、美国、75230
- Velocity Clinical Research, Dallas
-
Dallas、Texas、美国、75251
- FutureSearch Trials of Dallas
-
Houston、Texas、美国、77079
- PlanIt Research, PLLC
-
San Antonio、Texas、美国、78240
- Endeavor Clinical Trials
-
San Antonio、Texas、美国、78229
- Tekton Research - Fredericksburg Road
-
Weslaco、Texas、美国、78596
- Texas Valley Clinical Research
-
-
Virginia
-
Danville、Virginia、美国、24541
- Spectrum Medical, Inc.
-
-
Washington
-
Wenatchee、Washington、美国、98801
- Central Washington Health Services Association d/b/a Confluence Health
-
-
-
-
-
Buenos Aires、阿根廷、C1425AGC
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Buenos Aires、阿根廷、C1056ABI
- Centro de Investigaciones Metabólicas (CINME)
-
Buenos Aires、阿根廷、C1120AAC
- Centro Médico Viamonte
-
Buenos Aires、阿根廷、C1405BUB
- Consultorio de Investigación Clínica EMO SRL
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
W8M-MC-LAA2
- Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²)
- Have Type 2 Diabetes
- Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening
W8M-MC-CWMM:
- Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)
Exclusion Criteria:
W8M-MC-LAA2
-
Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
-
Have an on-going or history of bradyarrhythmia and/or sinus bradycardia
-
Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean <60 bpm) at screening
-
Have any of the following cardiovascular conditions within 6 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
-
Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2
-
Have a history of acute or chronic pancreatitis
-
Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening
-
All concomitant medications should be at a stable dose for at least 3 months prior to screening
W8M-MC-CWMM
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
- Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
- Have poorly controlled hypertension.
- Have a history of symptomatic gallbladder disease within the past 2 years
- Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
- Have a lifetime history of suicide attempts.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LY3841136 Dose 1
Participants will receive LY3841136 subcutaneously (SC) |
Administered SC |
|
实验性的:LY3841136 Dose 2
Participants will receive LY3841136 SC |
Administered SC |
|
实验性的:LY3841136 Dose 3
Participants will receive LY3841136 SC |
Administered SC |
|
实验性的:LY3841136 Dose 1 + Tirzepatide Dose 1
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
实验性的:LY3841136 Dose 2 + Tirzepatide Dose 1
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
实验性的:LY3841136 Dose 2 + Tirzepatide Dose 2
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
实验性的:LY3841136 Dose 3 + Tirzepatide Dose 3
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
有源比较器:Tirzepatide Dose 3
Participants will receive Tirzepatide SC |
Administered SC |
|
实验性的:LY3841136 Dose 2 + Tirzepatide Dose 3
Participants will receive LY3841136 SC and Tirzepatide SC |
Administered SC Administered SC |
|
安慰剂比较:Placebo
Participants will receive placebo administered SC. |
Administered SC |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
体重从基线变化的百分比
大体时间:基线,第 48 周
|
基线,第 48 周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
体重减轻 ≥ 5% 的参与者百分比
大体时间:第 48 周
|
第 48 周
|
|
体重减轻 ≥ 10% 的参与者百分比
大体时间:第 48 周
|
第 48 周
|
|
体重相对基线的变化
大体时间:基线,第 48 周
|
基线,第 48 周
|
|
A1c 血红蛋白 (HbA1c) 相对于基线的变化
大体时间:基线,第 48 周
|
基线,第 48 周
|
|
药代动力学(PK):LY3841136的曲线下面积(AUC)
大体时间:基线,第 48 周
|
基线,第 48 周
|
|
PK:LY3841136的最大浓度(Cmax)
大体时间:基线,第 48 周
|
基线,第 48 周
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 18809
- W8M-MC-LAA2 (其他标识符:Eli Lilly and Company)
- W8M-MC-CWMM Master Protocol (其他标识符:Eli Lilly and Company)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD 共享时间框架
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD 共享访问标准
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.